CATALENT

📅 Upcoming

🕒 Recent(90d)

News

• Immutep, Molecular cut workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Behind the scenes of 3 Big Pharma layoffs
  Three former employees of large pharmas, including Novo and Sanofi, share how they were let go. While they appreciated some aspects of their experiences, such as severance and outplacement resource…
  biospace · 4d ago
• FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
  Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
  biospace · 25d ago
• Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
  Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
  biospace · 1mo ago
• Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
  Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the FDA cited compliance problems at a third-party manufacturer.
  biospace · 1mo ago
• Multispecifics are transforming the CDMO development architecture
  Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.
  biospace · 2mo ago
• Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
  Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
  biospace · 2mo ago
• Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
  Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
  fiercebiotech · 2mo ago
• Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
  Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Lab…
  fiercebiotech · 2mo ago
• Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
  ElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.
  biospace · 3mo ago